Title |
Secondary Prevention of Cardiovascular Events With Long-Term Pravastatin in Patients With Diabetes or Impaired Fasting Glucose
|
---|---|
Published in |
Diabetes Care, October 2003
|
DOI | 10.2337/diacare.26.10.2713 |
Pubmed ID | |
Authors |
Anthony Keech, David Colquhoun, James Best, Adrienne Kirby, R. John Simes, David Hunt, Wendy Hague, Elaine Beller, Manjula Arulchelvam, Jennifer Baker, Andrew Tonkin |
Abstract |
Diabetes, a major health problem worldwide, increases the risk of cardiovascular disease and its associated mortality: The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) trial showed that cholesterol-lowering treatment with pravastatin reduced mortality and coronary heart disease (CHD) events in 9014 patients aged 31-75 years with CHD and total cholesterol 4.0-7.0 mmol/l. We measured the effects of pravastatin therapy, 40 mg/day over 6.0 years, on the risk of CHD death or nonfatal myocardial infarction and other cardiovascular outcomes in 1,077 LIPID patients with diabetes and 940 patients with impaired fasting glucose (IFG). |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 1% |
Unknown | 90 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 12 | 13% |
Student > Master | 11 | 12% |
Student > Bachelor | 10 | 11% |
Student > Doctoral Student | 6 | 7% |
Researcher | 5 | 5% |
Other | 22 | 24% |
Unknown | 25 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 33 | 36% |
Nursing and Health Professions | 10 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 7 | 8% |
Agricultural and Biological Sciences | 4 | 4% |
Computer Science | 2 | 2% |
Other | 7 | 8% |
Unknown | 28 | 31% |